Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 0.64% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Dec 19
3
With ROE of 9.56%, it has a Very Expensive valuation with a 0.14 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
HKD 11,001 Million ()
1.00
NA
0.00%
0.17
8.93%
0.13
Revenue and Profits:
Net Sales:
76,202 Million
(Quarterly Results - Jun 2025)
Net Profit:
3,620 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.05%
0%
-2.05%
6 Months
-2.05%
0%
-2.05%
1 Year
-11.09%
0%
-11.09%
2 Years
10.04%
0%
10.04%
3 Years
-16.08%
0%
-16.08%
4 Years
-15.13%
0%
-15.13%
5 Years
-3.78%
0%
-3.78%
Shanghai Pharmaceuticals Holding Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.97%
EBIT Growth (5y)
0.64%
EBIT to Interest (avg)
4.71
Debt to EBITDA (avg)
1.73
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
2.17
Tax Ratio
29.24%
Dividend Payout Ratio
30.34%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
10.03%
ROE (avg)
10.26%
Valuation key factors
Factor
Value
P/E Ratio
1
Industry P/E
Price to Book Value
0.14
EV to EBIT
4.06
EV to EBITDA
2.95
EV to Capital Employed
0.31
EV to Sales
0.11
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
7.76%
ROE (Latest)
9.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
76,202.00
75,440.50
1.01%
Operating Profit (PBDIT) excl Other Income
2,563.60
3,182.50
-19.45%
Interest
478.70
474.80
0.82%
Exceptional Items
40.90
40.40
1.24%
Consolidate Net Profit
3,619.90
1,753.70
106.42%
Operating Profit Margin (Excl OI)
23.30%
31.90%
-0.86%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 1.01% vs 6.60% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 106.42% vs 91.51% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
297,590.20
286,809.90
3.76%
Operating Profit (PBDIT) excl Other Income
12,260.00
11,664.70
5.10%
Interest
2,150.30
2,164.70
-0.67%
Exceptional Items
-348.50
141.10
-346.99%
Consolidate Net Profit
6,364.40
5,709.00
11.48%
Operating Profit Margin (Excl OI)
31.70%
31.60%
0.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.76% vs 6.65% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 11.48% vs -29.79% in Dec 2023
About Shanghai Pharmaceuticals Holding Co., Ltd. 
Shanghai Pharmaceuticals Holding Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






